Celtic Therapeutics and Bellus Health Initiate Confirmatory Phase III Clinical Study for Kiacta™ for the Treatment of AA Amyloidosis

December 15, 2010
BELLUS Health Inc. (TSX: BLU) and Celtic Therapeutics announced today that a global confirmatory phase III clinical study was initiated on December 14, 2010 for KIACTA™ (eprodisate).
Read the full press release

Celtic Therapeutics and Resolvyx Pharmaceuticals Announce an Alliance in Ophthalmology

October 26, 2010
Celtic Therapeutics Holdings L.P. (Celtic Therapeutics), a successor firm to Celtic Pharma, and Resolvyx Pharmaceuticals, Inc. (Resolvyx) announced today that they have entered into an option agreement relating to Resolvyx’s RX-10045, a late-stage program for the treatment of dry eye syndrome and other ophthalmic conditions.
Read the full press release

Spirogen and Celtic Therapeutics Commence a Phase II Clinical Trial of SG2000 in Ovarian Cancer

September 15, 2010
Spirogen Limited (the "Company") and CelticTherapeutics Holdings LP (“Celtic Therapeutics”) announced today the commencement of a Phase IIclinical trial of SG2000 in ovarian cancer.  
Read the full press release

Bellus Health and Celtic Therapeutics Enter Agreement for Bellus' Drug Candidate Kiacta™

April 29, 2010
BELLUS Health (TSX: BLU) and Celtic Therapeutics announced today that they have signed a final agreement pursuant to which Celtic Therapeutics will acquire and license worldwide rights related to the Phase III investigational product candidate KIACTA™ (eprodisate) for upfront payments of US$10 million, and will fund 100% of KIACTA™’s development costs through its confirmatory Phase III clinical study and other development activities, estimated at US$20 million. Read the full press release

CT Leads Series B Investment in Kolltan Pharmaceuticals

January 19, 2010
Kolltan Pharmaceuticals, Inc., a next-generation oncology therapeutics company, announced today that it has raised $10 million in investments and related payments from an affiliate of Celtic Therapeutics Holdings L.P. (“Celtic Therapeutics”) and Tichenor Ventures, LLC.
Read the full press release